BRIDGEBIO PHARMA INC. - COMMON STOCK

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

13 Jan 2025 11:00:00 By Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

08 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

13 Dec 2024 07:18:03 By Nasdaq GlobeNewswire

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

22 Nov 2024 19:11:30 By Nasdaq GlobeNewswire

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

18 Nov 2024 11:15:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update

12 Nov 2024 07:30:01 By Nasdaq GlobeNewswire

BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management

05 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024

24 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions

03 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

30 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events

27 Sep 2024 18:00:00 By Nasdaq GlobeNewswire

BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA

17 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

10 Sep 2024 16:45:00 By Nasdaq GlobeNewswire

BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program

10 Sep 2024 16:45:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension

30 Aug 2024 10:50:00 By Nasdaq GlobeNewswire

BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024

29 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in September Investor Events

28 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence

26 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia

19 Aug 2024 07:30:00 By Nasdaq GlobeNewswire